ACUITY-HORIZONS Score Calculator

ACUITY HORIZONS Score Explanation and Clinical Context The ACUITY HORIZONS risk score is a validated clinical tool that helps estimate the risk of major adverse cardiovascular events in patients presenting with acute coronary syndromes who undergo an early invasive strategy. This score incorporates age, renal function expressed through serum creatinine, hemodynamic status reflected by systolic blood pressure, and the presence of significant clinical features such as ST segment elevation myocardial infarction and congestive heart failure on presentation. Each of these variables reflects the severity of underlying disease and predicts short term and intermediate adverse outcomes.

Patients with higher age, impaired renal function, cardiogenic shock or severe hypotension, STEMI presentation, or pre existing heart failure are at significantly higher risk of mortality and ischemic complications. The ACUITY and HORIZONS studies were large multicenter clinical trials evaluating outcomes in acute coronary syndrome populations treated with contemporary invasive management and antithrombotic regimens. The risk model derived from these trials has been widely used to guide early risk stratification, inform decisions regarding antithrombotic therapy, and support invasive or pharmacologic treatment pathways.

This scoring system is considered practical because it uses readily available clinical variables that can be obtained at the time of first medical contact. Higher ACUITY HORIZONS scores identify patients who benefit from more intensive monitoring, careful hemodynamic optimization, and consideration of early revascularization strategies. Lower scores indicate better short term outcomes and lower ischemic event rates.

Although the score provides important prognostic information, it should be used in conjunction with clinical judgment, electrocardiographic findings, biomarkers of myocardial injury, and imaging results to determine the most appropriate treatment approach. References Stone GW et al. Bivalirudin during primary PCI in acute myocardial infarction.

New England Journal of Medicine. 2008. 358.

2218 to 2230. Lincoff AM et al. Prognostic assessment of ACUITY and HORIZONS trial data for acute coronary syndromes.

Circulation. 2011. 124.

1133 to 1143. Amsterdam EA et al. 2014 AHA ACC Guideline for the Management of Patients With Non ST Elevation Acute Coronary Syndromes.

Circulation. 2014. 130. e344 to e426.